Therapy-related myeloid neoplasm
MONDO:0006450Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.
Also known as: acute myeloid Leukaemias and myelodysplastic syndromes, therapy-related, therapy-related AML and MDS, therapy-related acute myeloid leukaemia and myelodysplastic syndrome, therapy-related acute myeloid leukemia and myelodysplastic syndrome, therapy-related myeloid neoplasm, TMN, therapy-related myeloid neoplasms
3100 clinical trials for this condition and its sub-types, 54 tagged with Therapy-related myeloid neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Cancer drug cocktail shows promise for tough blood cancers, but study halted early
Disease control Stopped earlyThis study tested a combination of two drugs, venetoclax and azacitidine, in 34 adults with high-risk blood cancers (MDS or CMML) that returned or didn't respond to earlier treatment. The goal was to find the safest dose and see if the combo could shrink or control the cancer. Th…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising combo for tough blood cancer hits snag, study stopped early
Disease control Stopped earlyThis study tested a combination of two drugs, venetoclax and azacitidine, for people with a high-risk type of bone marrow cancer called myelodysplastic syndrome (MDS) that either came back or didn't respond to treatment. The goal was to find the best dose and see how well it work…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental drug tested for Tough-to-Treat leukemia, but study stopped early
Disease control Stopped earlyThis phase 2 trial tested a drug called PF-05212384 in 10 people with certain types of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including cases linked to past cancer treatment or that had come back after other therapies. The drug was given weekly through an…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 26, 2026 14:44 UTC